首页> Cancer chemotherapy and pharmacology> Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models.

Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models.

导出 OA

翻译打印收藏纠错

第一作者： Nikki,DeAngelis

第一单位： Oncology Therapeutic Area, Janssen Research & Development, Spring House, PA, USA.

作者： Nikki,DeAngelis ^[1] ; Catherine,Ferrante ^[1] ; Gordon,Powers ^[2] ; Jocelyn,Sendecki ^[3] ; Bethany,Mattson ^[1] ; Darlene,Pizutti ^[1] ; Kathryn,Packman ^[1] ; Weirong,Wang ^[4] ; Kevin,Trouba ^[5] ; Rupesh,Nanjunda ^[2] ; John,Wheeler ^[2] ; Ray,Brittingham ^[2] ; Sheng-Jiun,Wu ^[2] ; Jinquan,Luo ^[2] ; Matthew V,Lorenzi ^[1] ; Raluca I,Verona ^[6]

作者单位： Oncology Therapeutic Area, Janssen Research & Development, Spring House, PA, USA. ^[1] Biologics Research, Janssen Research & Development, Spring House, PA, USA. ^[2] Translational Medicine and Early Development Statistics, Janssen Research & Development, Spring House, PA, USA. ^[3] Biologics Development Sciences, Janssen Research & Development, Spring House, PA, USA. ^[4] Nonclinical Safety, Janssen Research & Development, Spring House, Pennsylvania, USA. ^[5] Oncology Therapeutic Area, Janssen Research & Development, Spring House, PA, USA. rverona@its.jnj.com. ^[6]

关键词 Antitumor activity Immune checkpoint inhibitor Programmed cell death protein-1 T cell function Toxicokinetic assessment